

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Borean Pharma ApS	11/30/2007
RECEIVING PARTY DATA	
Name:	ImmunoNewco DK ApS
Street Address:	Raadhuspladesen 4
Internal Address:	c/o Lett Law Firm
City:	Copenhagen V
State/Country:	DENMARK
Postal Code:	DK-1550
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	12405003
Application Number:	12405021
CORRESPONDENCE DATA	
Fax Number:	(312)913-0002
Phone:	3129130001
Email:	docketing@mbhb.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	McDonnell Boehnen Hulbert & Berghoff LLP
Address Line 1:	300 S. Wacker Dr.
Address Line 4:	Chicago, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	08-347-US-DIV, -CON2
NAME OF SUBMITTER:	Donald L. Zuhn, Jr.
Total Attachments: 36 source=2007-11-30_Assignment#page1.tif	

CH \$80.00 12405003

source=2007-11-30\_Assignment#page2.tif  
source=2007-11-30\_Assignment#page3.tif  
source=2007-11-30\_Assignment#page4.tif  
source=2007-11-30\_Assignment#page5.tif  
source=2007-11-30\_Assignment#page6.tif  
source=2007-11-30\_Assignment#page7.tif  
source=2007-11-30\_Assignment#page8.tif  
source=2007-11-30\_Assignment#page9.tif  
source=2007-11-30\_Assignment#page10.tif  
source=2007-11-30\_Assignment#page11.tif  
source=2007-11-30\_Assignment#page12.tif  
source=2007-11-30\_Assignment#page13.tif  
source=2007-11-30\_Assignment#page14.tif  
source=2007-11-30\_Assignment#page15.tif  
source=2007-11-30\_Assignment#page16.tif  
source=2007-11-30\_Assignment#page17.tif  
source=2007-11-30\_Assignment#page18.tif  
source=2007-11-30\_Assignment#page19.tif  
source=2007-11-30\_Assignment#page20.tif  
source=2007-11-30\_Assignment#page21.tif  
source=2007-11-30\_Assignment#page22.tif  
source=2007-11-30\_Assignment#page23.tif  
source=2007-11-30\_Assignment#page24.tif  
source=2007-11-30\_Assignment#page25.tif  
source=2007-11-30\_Assignment#page26.tif  
source=2007-11-30\_Assignment#page27.tif  
source=2007-11-30\_Assignment#page28.tif  
source=2007-11-30\_Assignment#page29.tif  
source=2007-11-30\_Assignment#page30.tif  
source=2007-11-30\_Assignment#page31.tif  
source=2007-11-30\_Assignment#page32.tif  
source=2007-11-30\_Assignment#page33.tif  
source=2007-11-30\_Assignment#page34.tif  
source=2007-11-30\_Assignment#page35.tif  
source=2007-11-30\_Assignment#page36.tif

**THIS INTELLECTUAL PROPERTY ASSIGNMENT** (this "Assignment") is dated as of November 30, 2007 by and between Borean Pharma ApS ("Assignor") and ImmunoNewco DK ApS ("Assignee").

**WITNESSETH:**

**WHEREAS**, Assignor and Assignee are parties to that certain Asset Purchase Agreement dated as of November 30, 2007 (the "Purchase Agreement"); and

**WHEREAS**, as partial consideration for the payments to be made by Assignee to Assignor under the Purchase Agreement, Assignor has agreed to execute this Intellectual Property Assignment.

**NOW, THEREFORE**, intending to be bound, the parties hereto hereby agree as follows:

1. Assignor hereby transfers and assigns to Assignee, all of Assignor's worldwide right, title and interest in and to all Intellectual Property and Intellectual Property Rights (as defined in Exhibit A hereto) and related goodwill of Assignor and its affiliates (including, but not limited to the Intellectual Property and Intellectual Property Rights identified on Exhibit B hereto), and all claims (including claims for past infringement or misappropriation of Intellectual Property and Intellectual Property Rights) and causes of action of the Assignor and its affiliates against other persons (regardless of whether or not such claims and causes of action have been asserted by Assignor), and all rights of indemnity, warranty rights, rights of contribution, rights to refunds, rights of reimbursement and other rights of recovery possessed by Assignor (regardless of whether such rights are currently exercisable).
2. Assignor hereby represents that it will not contest the registration, use or enforcement by Assignee of any of the Intellectual Property or Intellectual Property Rights and hereby waives any claims against Assignee relating to the use by Assignee or any assignee of Assignee of any of the Intellectual Property and Intellectual Property Rights. Assignor will not use, register or attempt to register or otherwise secure any trademark, service mark, domain name, trade name (including any corporate name), copyright, or any other rights in any of the Intellectual Property or Intellectual Property Rights.
3. Assignee does not assume any liabilities, claims or obligations of any kind arising from Assignor's use of any of the Intellectual Property and Intellectual Property Rights.
4. Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as Assignor's agent and attorney-in-fact, solely to act on Assignor's behalf to execute and file any such lawfully permitted documents and to further the prosecution and issuance of Intellectual Property and Intellectual Property Rights or similar protections thereon with the same legal force and effect as if executed by Assignor.
5. This Assignment shall be binding upon the parties hereto and their respective successors and assigns.

6. In the event that any of the terms of this Assignment Agreement conflict in any way with the provisions of the Purchase Agreement, the Purchase Agreement shall govern.

7. This Assignment Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute one instrument.

8. This Assignment Agreement shall be governed by and construed and interpreted in accordance with the substantive laws of the Kingdom of Denmark, i.e. the laws of Denmark without regard to the Danish conflict of law principles.

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS

By Jesper Zeuthen  
Name Jesper Zeuthen  
Title Chairman of the  
Board

ASSIGNEE

.....ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Boreon Pharma ApS

By [Signature]  
Name John Haldach  
Title CEO

ASSIGNEE

.....ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.


ASSIGNOR

Borean Pharma ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By   
Name Andrew F. Schwab  
Title Director

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By Phyllis E. Whitely  
Name Phyllis E. Whitely, Ph.D.  
Title Director

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_



IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS


By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By   
Name Richard Ulevitch, Ph.D.  
Title Director

## Exhibit A

"Intellectual Property" shall mean Patents, Marks, Copyrights, Proprietary Information, utility models, data, formulae, inventions (whether or not patentable), know-how, methods, processes, proprietary information, protocols, specifications, techniques, works of authorship and other forms of technology (whether or not embodied in any tangible form and including all tangible embodiments of the foregoing, such as laboratory notebooks, samples, studies and summaries).

"Intellectual Property Rights" shall mean all past, present, and future rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: (A) trade secret rights; (B) rights associated with works of authorship, including exclusive exploitation rights, Copyrights, moral rights and mask works; (C) Marks and trade name rights and similar rights; (D) Patent and industrial property rights; (E) other proprietary rights in Intellectual Property; (F) other proprietary rights in Intellectual Property of every kind and nature; and (G) rights in or relating to registrations, renewals, extensions, combinations, divisions, and reissues of, and applications for, any of the rights referred to in clauses "(A)" through "(F)" above; and (G) the goodwill of the Seller related to any of the rights referred to in clauses "(A)" through "(F)" above.

"Copyrights" means all right, title and interest in and to all original works of authorship, whether registered or unregistered, and all United States, Danish and foreign registrations and pending applications for the same.

"Marks" means registered and unregistered trademarks, service marks, trade names, assumed names, brand names and logotypes (including translations, adaptations, derivations and combinations), and related applications, registrations and renewals. Marks includes, by way of example and not limitation, Seller's name and all fictitious business names of Seller.

"Patents" means United States, Danish and foreign patents, patent applications and patent disclosures and related reissues, continuations, continuations-in-part, revisions, extensions and reexaminations, including substantial equivalents thereto.

"Proprietary Information" means trade secrets and proprietary or confidential business information, including, without limitation, (i) ideas, formulas, discoveries and inventions (whether patentable or unpatentable, and whether or not reduced to practice); (ii) know-how; and (iii) confidential computer source code, programs, software and documentation.

## Exhibit B

- (i) Seller's C-type lectin domain (CTLD) libraries, used to identify drug candidates, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (ii) Seller's trimerisation technology, combining CTLD drug candidates or approved pharmaceuticals into single trimeric molecular units, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (iii) Seller's protein production technology, based on unique fusion protein and refolding methods allowing production of protein in E.coli, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (iv) Seller's program directed to its proprietary CTLD-derived trimeric cytokine antagonist, including patent rights, manufacturing and other technical know-how, preclinical and clinical data, regulatory filings, existing quantities of compound, and other biological and chemical materials related thereto;
- (v) Seller's combining mannose binding protein (MBP) and or its derivatives to be used as a single molecular units, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (vi) all "Patent Rights" in respect of the "Newco Field" pursuant to the Patent Co-Ownership Agreement dated June 21, 2006, by and between Roche Bio Denmark A/S and Borean Pharma A/S;
- (vii) Protein Refolding

### Description of the invention:

In vitro refolding of proteins by subjecting the proteins to a series of renaturing and denaturing steps

### Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet

### List of patents and patent applications claiming priority from:

Danish patent application No.: 130/93; Filing date: 04.02.1993.

Danish patent application No.: 139/93; Filing date: 05.02.1993.

International Patent Application No.: PCT/GB93/02492; Filing date: 03.12.1993.

Joint ownership with F. Hoffmann-La Roche Ltd.

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Austria (AT)	BOR 00001/ATZ	Granted	94906891.0	E-241642 (0686162)	EP
Australia (AU)	BOR 00001/AUT	Granted	60380/94	674568	Via PCT
Belgium (BE)	BOR 00001/BEZ	Granted	94906891.0	0686162	EP

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Canada (CA)	BOR 00001/CAT	Granted	CA1994002155335	2,155,335	Via PCT
Switzerland (CH)	BOR 00001/CHZ	Granted	94906891.0	0686162	EP
Germany (DE)	BOR 00001/DEZ	Granted	94906891.0	69432744.1	EP
Denmark (DK)	BOR 00001/DKZ	Granted	94906891.0	DK/EP 0686162	EP
Spain (ES)	BOR 00001/ESZ	Granted	94906891.0	EP0686162	EP
Finland (FI)	BOR 00001/FIT	Granted	FI1995000953705	113272	Via PCT
France (FR)	BOR 00001/FRZ	Granted	94906891.0	0686162	EP
United Kingdom (GB)	BOR 00001/GBZ	Granted	94906891.0	0686162	EP
Eire/Ireland (IE)	BOR 00001/IEZ	Granted	94906891.0	0686162	EP
Italy (IT)	BOR 00001/ITZ	Granted	94906891.0	0686162	EP
Japan (JP)	BOR 00001/JPT	Granted	JP1994000517544	3695467	Via PCT
Korea, South (KR)	BOR 00001/KRT	Granted	95-703244	310739	Via PCT
Netherlands (NL)	BOR 00001/NLZ	Granted	94906891.0	0686162	EP
Norway (NO)	BOR 00001/NOT	Granted	NO1995000952989	316.274	Via PCT
New Zealand (NZ)	BOR 00001/NZT	Granted	NZ1994000261571	261571	Via PCT
Sweden (SE)	BOR 00001/SEZ	Granted	94906891.0	0686162	EP
USA (US)	BOR 00001/UST/N1	Granted	08/469,486	US 5,739,281	Continuati on
USA (US)	BOR 00001/UST/N2	Granted	08/469,658	US 5,917,018	Divisional
India (IN)	BOR 00001/INT	Expired	90/MAS/94	179831	Via PCT
USA (US)	BOR 00001/UST	Abandon ed	8/192,060		Via PCT
USA (US)	BOR 00001/UST/N3	Abandon ed	08/592,876		Divisional
WO	BOR 00001/WO	Expired	PCT/DK94/00054		PCT

(viii) Trimerisation Technology

Description of the invention:

Trimeric and multifunctional polypeptides based on structural elements derived from the tetranectin protein.

Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen

List of patents and patent applications claiming priority from:

Danish patent application No.: PA 1997 00685; Filing date: 11.06.1997.

Joint ownership with F. Hoffmann-La Roche-Ltd.

COUNTRY	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Austria (AT)	BOR 00002/ATZ	Granted	98929225.5	E 282092 (1012280)	EP
Australia (AU)	BOR 00002/AUT	Granted	79065/98	736707	Via PCT
Belgium (BE)	BOR 00002/BEZ	Granted	98929225.5	BE/EP 1012280	EP
Canada (CA)	BOR 00002/CAT	Pending	2,304,254		Via PCT
Switzerland (CH)	BOR 00002/CHZ	Granted	98929225.5	CH/EP 1012280	EP
Germany (DE)	BOR 00002/DEZ	Granted	98929225.5	DE 69827507	EP
Denmark (DK)	BOR 00002/DKZ	Granted	98929225.5	DK/EP 1012280	EP
Spain (ES)	BOR 00002/ESZ	Granted	98929225.5	2231991	EP
Finland (FI)	BOR 00002/FIZ	Granted	98929225.5	FI/EP 1012280	EP
France (FR)	BOR 00002/FRZ	Granted	98929225.5	FR/EP 1012280	EP
United Kingdom (GB)	BOR 00002/GBZ	Granted	98929225.5	GB/EP 1012280	EP
Greece (GR)	BOR 00002/GRZ	Granted	98929225.5	GR/EP 1012280	EP
Eire/Ireland (IE)	BOR 00002/IEZ	Granted	98929225.5	IE/EP 1012280	EP
Italy (IT)	BOR 00002/ITZ	Granted	98929225.5	1012280	EP
Luxembourg	BOR	Granted	98929225.5	LU/EP 1012280	EP

(LU)	00002/LUZ				
Monaco (MC)	BOR 00002/MCZ	Granted	98929225.5	MC/EP 1012280	EP
Netherlands (NL)	BOR 00002/NLZ	Granted	98929225.5	NL/EP 1012280	EP
Portugal (PT)	BOR 00002/PTZ	Granted	98929225.5	PT/EP 1012280	EP
Sweden (SE)	BOR 00002/SEZ	Granted	98929225.5	SE/EP 1012280	EP
USA (US)	BOR 00002/UST/ N1	Pending	11/452,434		Continua tion
USA (US)		Lapsed	09/445,576		Via PCT
WO		Expired	PCT/DK98/00245		

(ix) CTLD library

Description of the invention:

Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains

Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2000 01872; Filing date: 13.12.2000

US provisional patent application No.: 60/272,098; Filing date: 28.02.2001

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR 00003/AUT	Granted	2002221568	2002221568	Via PCT
Brazil (BR)	BOR 00003/BRT	Pending	PI0116138-5		Via PCT
Canada (CA)	BOR 00003/CAT	Pending	2,430,953		Via PCT
China (CN)	BOR 00003/CNT	Pending	01821632.3		Via PCT
European Patent Office (EP)	BOR 00003/EPT	Pending	01270552.1		EP, via PCT
India (IN)	BOR 00003/INT	Pending	907/DELNP/2003		Via PCT
Japan (JP)	BOR 00003/JPT	Pending	2002-549720		Via PCT
Korea, South (KR)	BOR 00003/KRT	Pending	2003-7007858		Via PCT

Norway (NO)	BOR 00003/NOT	Pending	20032663		Via PCT
New Zealand (NZ)	BOR 00003/NZT	Granted	526312	526312	Via PCT
USA (US)		Pending	11/633040		Divisional
South Africa (ZA)	BOR 00003/ZAT	Granted	2003/4459	2003/4459	Via PCT
WO		Expired	PCT/DK01/00825		
USA (US)		Abandoned	10/450,472		

(x) Multimerised growth hormone

Case dead

Description of the invention:

Multimerised growth hormone polypeptides with increased biological activity

Inventors:

Thor Las Holtet

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2000 01064; Filing date: 05.07.2002

US provisional patent application No.: 60/393,383; Filing date: 05.07.2002

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
WO	BOR 00004/WO	Abandoned	PCT/DK/00428		Via PCT

(xi) Trimeric cytokine binder

Description of the invention:

Trimeric specific binder capable of binding a trimeric cytokine (e.g. TNF)

Inventors:

Mikkel Holmen Andersen, Helle Krogh Ottow, Thor Las Holtet

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2002 01634; Filing date: 29.10.2002

US provisional patent application No.: 60/421,807; Filing date: 29.10.2002

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR	Pending	2003277828		Via

	00005/AUT				PCT
Canada (CA)	BOR 00005/CAT	Pending	2,503,697		Via PCT
China (CN)	BOR 00005/CNT	Pending	200380104658.7		Via PCT
European Patent Office (EP)	BOR 00005/EPT	Pending	03769251.4		Via PCT
Japan (JP)	BOR 00005/JPT	Pending	2004-547447		Via PCT
USA (US)	BOR 00005/UST	Pending	10/533,290		Via PCT
WO		Expired	PCT/DK2003/000735		

(xii) Granzyme B cleavage of fusion proteins

Description of the invention:

Use of Granzyme B for cleavage of fusion proteins; Fusion proteins comprising a Granzyme B cleavage site; Human Granzyme B protease variant where Cys 228 is mutated to Phe.

Inventors:

Charlotte Harkjær Fynbo, Rikke Høegh Lorentzen

List of patents and patent applications claiming priority from:

Danish patent application No.: PA 2003 00616; Filing date: 23.04.2003.

USA, provisional patent application No.: 60/464,663; Filing date: 23.04.2003.

Joint ownership with F. Hoffmann-La Roche Ltd.

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia	BOR 00006/AUT	Pending	2004232405		Via PCT
Canada	BOR 00006/CAT	Pending	2,523,101		Via PCT
China	BOR 00006/CNT	Pending	200480014688.3		Via PCT
European Patent Office	BOR 00006/EPT	Pending	04729047.3		EP
India	BOR 00006/INT	Pending	2069/KOLNP/2005		Via PCT
Japan	BOR 00006/JPT	Pending	2006-504365		Via PCT



New Zealand	BOR 00006/NZT	Registered	543557		Via PCT
New Zealand		Pending	561162		Divisional
USA	BOR 00006/UST	Pending	10/553,869		Via PCT
WO		Expired	PCT/DK2004/000282		

(xiii) EPO-depot

Case dead

Description of the invention:

Pharmaceutical composition comprising a complex of non-covalently associated erythropoietin (EPO) and soluble erythropoietin binding protein (EPO-bp) and the use of such a composition in therapy, in particular for the treatment of diseases or conditions involving low red blood cell levels or deficient blood cell production.

Inventors:

Thor Las Holtet

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
DK	BOR 00007/DK/P1	Abandoned	PA 2003 01341		Priority

(xiv) HIV fusion inhibitor

Description of the invention:

Multimeric fusion proteins exhibiting anti-viral activity which comprises the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein fused to a multimerisation domain peptide.

Inventors:

Michael Etzerodt

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2004 00283; Filing date: 23-02-2004

US provisional patent application No.: 60/546,200; Filing date: 23.02.2004

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Brazil (BR)	BOR 00010/BRT	Pending	PI0507949-7		Via PCT
China (CN)	BOR	Pending	200580011458.6		Via PCT

	00010/CNT				
European Patent Office (EP)	BOR 00010/EPT	Pending	05706783.7		Via PCT
India (IN)	BOR 00010/INT	Pending			Via PCT
USA (US)	BOR 00010/US	Pending	11/064,115		Regular
WO		Expired	PCT/DK2005/000121		

(xv) TNF antagonists

Description of the invention:

Polypeptides and related compounds that can bind and act as antagonists of TNF.

Inventors:

Mikkel Holmen Andersen, Mette Munch, Helle Krogh Ottow, Thor Las Holtet, Josephus Dirk Nieland

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2004 01813; Filing date: 22.11.2004

US provisional patent application No.: 60/629,343; Filing date: 22.11.2004

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR 00011/AUT	Pending	2005306168		Via PCT
Brazil (BR)	BOR 00011/BRT	Pending	PI0518042-2		Via PCT
Canada (CA)	BOR 00011/CAT	Pending	2587948		Via PCT
China (CN)	BOR 00011/CNT	Pending	200580046429.3		Via PCT
European Patent Office (EP)	BOR 00011/EPT	Pending	05803991.8		Via PCT
India (IN)	BOR 00011/INT	Pending			Via PCT
Japan (JP)	BOR 00011/JPT	Pending	2007-541691		Via PCT
Korea, South (KR)	BOR 00011/KRT	Pending	2007-7013927		Via PCT
Norway (NO)	BOR 00011/NOT	Pending	20073239		Via PCT
New Zealand (NZ)	BOR 00011/NZT	Pending	555353		Via PCT

USA (US)	BOR 00011/UST	Pending	11/719,942		Via PCT
South Africa (ZA)	BOR 00011/ZAT	Pending	2007/05594		Via PCT
WO	BOR 00011/WO	Expired	PCT/DK2005/000742		PCT

(xvi) HSP70 domain

Description of the invention:

Domain in Heat Shock Protein 70 involved in the induction of autoimmune diseases such as Vitiligo

Inventors:

Josephus Dirk Nieland, Thor Las Holtet, Isabelle Caroline Le Poole

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
USA (US)	BOR 00012/UST	Pending	60/904,550		Provisional
USA (US)		Pending	60/960,022		Provisional

(xvii) Trimeric IL-Ra

Description of the invention:

Trimeric interleukin 1 receptor antagonist (IL-1Ra)

Inventors:

Josephus Dirk Nieland, Thor Las Holtet, Mikkel Holmen Andersen

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
USA (US)	BOR 00013/UST	Pending	60/978,254		Provisional

(xviii) MPB-DC-SIGN

Description of the invention:

Fusion proteins for treating cancer

Inventors:

Mikkel Holmen Andersen, Michael Etzerodt, Thor Las Holtet, Majbritt Hauge Kyneb

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
DENMARK (DK)		Pending	PA 2007 01589		Provisional
USA (US)		Pending	60,996,288		Provisional

**THIS INTELLECTUAL PROPERTY ASSIGNMENT** (this "Assignment") is dated as of November 30, 2007 by and between Borean Pharma ApS ("Assignor") and ImmunoNewco DK ApS ("Assignee").

**WITNESSETH:**

**WHEREAS**, Assignor and Assignee are parties to that certain Asset Purchase Agreement dated as of November 30, 2007 (the "Purchase Agreement"); and

**WHEREAS**, as partial consideration for the payments to be made by Assignee to Assignor under the Purchase Agreement, Assignor has agreed to execute this Intellectual Property Assignment.

**NOW, THEREFORE**, intending to be bound, the parties hereto hereby agree as follows:

1. Assignor hereby transfers and assigns to Assignee, all of Assignor's worldwide right, title and interest in and to all Intellectual Property and Intellectual Property Rights (as defined in Exhibit A hereto) and related goodwill of Assignor and its affiliates (including, but not limited to the Intellectual Property and Intellectual Property Rights identified on Exhibit B hereto), and all claims (including claims for past infringement or misappropriation of Intellectual Property and Intellectual Property Rights) and causes of action of the Assignor and its affiliates against other persons (regardless of whether or not such claims and causes of action have been asserted by Assignor), and all rights of indemnity, warranty rights, rights of contribution, rights to refunds, rights of reimbursement and other rights of recovery possessed by Assignor (regardless of whether such rights are currently exercisable).
2. Assignor hereby represents that it will not contest the registration, use or enforcement by Assignee of any of the Intellectual Property or Intellectual Property Rights and hereby waives any claims against Assignee relating to the use by Assignee or any assignee of Assignee of any of the Intellectual Property and Intellectual Property Rights. Assignor will not use, register or attempt to register or otherwise secure any trademark, service mark, domain name, trade name (including any corporate name), copyright, or any other rights in any of the Intellectual Property or Intellectual Property Rights.
3. Assignee does not assume any liabilities, claims or obligations of any kind arising from Assignor's use of any of the Intellectual Property and Intellectual Property Rights.
4. Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as Assignor's agent and attorney-in-fact, solely to act on Assignor's behalf to execute and file any such lawfully permitted documents and to further the prosecution and issuance of Intellectual Property and Intellectual Property Rights or similar protections thereon with the same legal force and effect as if executed by Assignor.
5. This Assignment shall be binding upon the parties hereto and their respective successors and assigns.

6. In the event that any of the terms of this Assignment Agreement conflict in any way with the provisions of the Purchase Agreement, the Purchase Agreement shall govern.

7. This Assignment Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which shall constitute one instrument.

8. This Assignment Agreement shall be governed by and construed and interpreted in accordance with the substantive laws of the Kingdom of Denmark, i.e. the laws of Denmark without regard to the Danish conflict of law principles.

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS

By Jesper Zenithen  
Name Jesper Zenithen  
Title Chairman of the  
Board

ASSIGNEE

.....ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

PATENT

REEL: 027780 FRAME: 0786

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Boreon Pharma ApS

By [Signature]  
Name Joakim Holm  
Title CEO

ASSIGNEE

.....ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_



IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.


ASSIGNOR

Borean Pharma ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By   
Name Andrew J. Schwab  
Title Director

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By Phyllis E. Whiteley  
Name Phyllis E. Whiteley, Ph.D.  
Title Director

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

ASSIGNOR

Borean Pharma ApS


By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

ASSIGNEE

ImmunoNewco DK ApS

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By \_\_\_\_\_  
Name \_\_\_\_\_  
Title \_\_\_\_\_

By   
Name Richard Ulevitch, Ph.D.  
Title Director

### Exhibit A

"Intellectual Property" shall mean Patents, Marks, Copyrights, Proprietary Information, utility models, data, formulae, inventions (whether or not patentable), know-how, methods, processes, proprietary information, protocols, specifications, techniques, works of authorship and other forms of technology (whether or not embodied in any tangible form and including all tangible embodiments of the foregoing, such as laboratory notebooks, samples, studies and summaries).

"Intellectual Property Rights" shall mean all past, present, and future rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: (A) trade secret rights; (B) rights associated with works of authorship, including exclusive exploitation rights, Copyrights, moral rights and mask works; (C) Marks and trade name rights and similar rights; (D) Patent and industrial property rights; (E) other proprietary rights in Intellectual Property; (F) other proprietary rights in Intellectual Property of every kind and nature; and (G) rights in or relating to registrations, renewals, extensions, combinations, divisions, and reissues of, and applications for, any of the rights referred to in clauses "(A)" through "(F)" above; and (G) the goodwill of the Seller related to any of the rights referred to in clauses "(A)" through "(F)" above.

"Copyrights" means all right, title and interest in and to all original works of authorship, whether registered or unregistered, and all United States, Danish and foreign registrations and pending applications for the same.

"Marks" means registered and unregistered trademarks, service marks, trade names, assumed names, brand names and logotypes (including translations, adaptations, derivations and combinations), and related applications, registrations and renewals. Marks includes, by way of example and not limitation, Seller's name and all fictitious business names of Seller.

"Patents" means United States, Danish and foreign patents, patent applications and patent disclosures and related reissuances, continuations, continuations-in-part, revisions, extensions and reexaminations, including substantial equivalents thereto.

"Proprietary Information" means trade secrets and proprietary or confidential business information, including, without limitation, (i) ideas, formulas, discoveries and inventions (whether patentable or unpatentable, and whether or not reduced to practice); (ii) know-how; and (iii) confidential computer source code, programs, software and documentation.

## Exhibit B

- (i) Seller's C-type lectin domain (CTLD) libraries, used to identify drug candidates, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (ii) Seller's trimerisation technology, combining CTLD drug candidates or approved pharmaceuticals into single trimeric molecular units, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (iii) Seller's protein production technology, based on unique fusion protein and refolding methods allowing production of protein in E.coli, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (iv) Seller's program directed to its proprietary CTLD-derived trimeric cytokine antagonist, including patent rights, manufacturing and other technical know-how, preclinical and clinical data, regulatory filings, existing quantities of compound, and other biological and chemical materials related thereto;
- (v) Seller's combining mannose binding protein (MBP) and or its derivatives to be used as a single molecular units, including any patent rights, manufacturing and other technical know-how, and biological and chemical materials related thereto;
- (vi) all "Patent Rights" in respect of the "Newco Field" pursuant to the Patent Co-Ownership Agreement dated June 21, 2006, by and between Roche Bio Denmark A/S and Borean Pharma A/S;
- (vii) Protein Refolding

### Description of the invention:

In vitro refolding of proteins by subjecting the proteins to a series of renaturing and denaturing steps

### Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet

### List of patents and patent applications claiming priority from:

Danish patent application No.: 130/93; Filing date: 04.02.1993.

Danish patent application No.: 139/93; Filing date: 05.02.1993.

International Patent Application No.: PCT/GB93/02492; Filing date: 03.12.1993.

Joint ownership with F. Hoffmann-La Roche Ltd.

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Austria (AT)	BOR 00001/ATZ	Granted	94906891.0	E-241642 (0686162)	EP
Australia (AU)	BOR 00001/AUT	Granted	60380/94	674568	Via PCT
Belgium (BE)	BOR 00001/BEZ	Granted	94906891.0	0686162	EP

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Canada (CA)	BOR 00001/CAT	Granted	CA1994002155335	2,155,335	Via PCT
Switzerland (CH)	BOR 00001/CHZ	Granted	94906891.0	0686162	EP
Germany (DE)	BOR 00001/DEZ	Granted	94906891.0	69432744.1	EP
Denmark (DK)	BOR 00001/DKZ	Granted	94906891.0	DK/EP 0686162	EP
Spain (ES)	BOR 00001/ESZ	Granted	94906891.0	EP0686162	EP
Finland (FI)	BOR 00001/FIT	Granted	FI1995000953705	113272	Via PCT
France (FR)	BOR 00001/FRZ	Granted	94906891.0	0686162	EP
United Kingdom (GB)	BOR 00001/GBZ	Granted	94906891.0	0686162	EP
Eire/Ireland (IE)	BOR 00001/IEZ	Granted	94906891.0	0686162	EP
Italy (IT)	BOR 00001/ITZ	Granted	94906891.0	0686162	EP
Japan (JP)	BOR 00001/JPT	Granted	JP1994000517544	3695467	Via PCT
Korea, South (KR)	BOR 00001/KRT	Granted	95-703244	310739	Via PCT
Netherlands (NL)	BOR 00001/NLZ	Granted	94906891.0	0686162	EP
Norway (NO)	BOR 00001/NOT	Granted	NO1995000952989	316.274	Via PCT
New Zealand (NZ)	BOR 00001/NZT	Granted	NZ1994000261571	261571	Via PCT
Sweden (SE)	BOR 00001/SEZ	Granted	94906891.0	0686162	EP
USA (US)	BOR 00001/UST/N1	Granted	08/469,486	US 5,739,281	Continuation
USA (US)	BOR 00001/UST/N2	Granted	08/469,658	US 5,917,018	Divisional
India (IN)	BOR 00001/INT	Expired	90/MAS/94	179831	Via PCT
USA (US)	BOR 00001/UST	Abandoned	8/192,060		Via PCT
USA (US)	BOR 00001/UST/N3	Abandoned	08/592,876		Divisional
WO	BOR 00001/WO	Expired	PCT/DK94/00054		PCT

(viii) Trimerisation Technology

Description of the invention:

Trimeric and multifunctional polypeptides based on structural elements derived from the tetranectin protein.

Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen

List of patents and patent applications claiming priority from:

Danish patent application No.: PA 1997 00685; Filing date: 11.06.1997.

Joint ownership with F. Hoffmann-La Roche-Ltd.

COUNTRY	CASE REF	STATUS	APPLICATION NO	PATENT NO	TYPE
Austria (AT)	BOR 00002/ATZ	Granted	98929225.5	E 282092 (1012280)	EP
Australia (AU)	BOR 00002/AUT	Granted	79065/98	736707	Via PCT
Belgium (BE)	BOR 00002/BEZ	Granted	98929225.5	BE/EP 1012280	EP
Canada (CA)	BOR 00002/CAT	Pending	2,304,254		Via PCT
Switzerland (CH)	BOR 00002/CHZ	Granted	98929225.5	CH/EP 1012280	EP
Germany (DE)	BOR 00002/DEZ	Granted	98929225.5	DE 69827507	EP
Denmark (DK)	BOR 00002/DKZ	Granted	98929225.5	DK/EP 1012280	EP
Spain (ES)	BOR 00002/ESZ	Granted	98929225.5	2231991	EP
Finland (FI)	BOR 00002/FIZ	Granted	98929225.5	FI/EP 1012280	EP
France (FR)	BOR 00002/FRZ	Granted	98929225.5	FR/EP 1012280	EP
United Kingdom (GB)	BOR 00002/GBZ	Granted	98929225.5	GB/EP 1012280	EP
Greece (GR)	BOR 00002/GRZ	Granted	98929225.5	GR/EP 1012280	EP
Eire/Ireland (IE)	BOR 00002/IEZ	Granted	98929225.5	IE/EP 1012280	EP
Italy (IT)	BOR 00002/ITZ	Granted	98929225.5	1012280	EP
Luxembourg	BOR	Granted	98929225.5	LU/EP 1012280	EP

(LU)	00002/LUZ				
Monaco (MC)	BOR 00002/MCZ	Granted	98929225.5	MC/EP 1012280	EP
Netherlands (NL)	BOR 00002/NLZ	Granted	98929225.5	NL/EP 1012280	EP
Portugal (PT)	BOR 00002/PTZ	Granted	98929225.5	PT/EP 1012280	EP
Sweden (SE)	BOR 00002/SEZ	Granted	98929225.5	SE/EP 1012280	EP
USA (US)	BOR 00002/UST/ N1	Pending	11/452,434		Continua tion
USA (US)		Lapsed	09/445,576		
WO		Expired	PCT/DK98/00245		Via PCT

(ix) CTLD library

Description of the invention:

Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains

Inventors:

Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2000 01872; Filing date: 13.12.2000

US provisional patent application No.: 60/272,098; Filing date: 28.02.2001

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR 00003/AUT	Granted	2002221568	2002221568	Via PCT
Brazil (BR)	BOR 00003/BRT	Pending	PI0116138-5		Via PCT
Canada (CA)	BOR 00003/CAT	Pending	2,430,953		Via PCT
China (CN)	BOR 00003/CNT	Pending	01821632.3		Via PCT
European Patent Office (EP)	BOR 00003/EPT	Pending	01270552.1		EP, via PCT
India (IN)	BOR 00003/INT	Pending	907/DELNP/2003		Via PCT
Japan (JP)	BOR 00003/JPT	Pending	2002-549720		Via PCT
Korea, South (KR)	BOR 00003/KRT	Pending	2003-7007858		Via PCT



Norway (NO)	BOR 00003/NOT	Pending	20032663		Via PCT
New Zealand (NZ)	BOR 00003/NZT	Granted	526312	526312	Via PCT
USA (US)		Pending	11/633040		Divisional
South Africa (ZA)	BOR 00003/ZAT	Granted	2003/4459	2003/4459	Via PCT
WO		Expired	PCT/DK01/00825		
USA (US)		Abandoned	10/450,472		

(x) Multimerised growth hormone

Case dead

Description of the invention:

Multimerised growth hormone polypeptides with increased biological activity

Inventors:

Thor Las Holtet

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2000 01064; Filing date: 05.07.2002

US provisional patent application No.: 60/393,383; Filing date: 05.07.2002

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
WO	BOR 00004/WO	Abandoned	PCT/DK/00428		Via PCT

(xi) Trimeric cytokine binder

Description of the invention:

Trimeric specific binder capable of binding a trimeric cytokine (e.g. TNF)

Inventors:

Mikkel Holmen Andersen, Helle Krogh Ottow, Thor Las Holtet

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2002 01634; Filing date: 29.10.2002

US provisional patent application No.: 60/421,807; Filing date: 29.10.2002

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR	Pending	2003277828		Via

	00005/AUT				PCT
Canada (CA)	BOR 00005/CAT	Pending	2,503,697		Via PCT
China (CN)	BOR 00005/CNT	Pending	200380104658.7		Via PCT
European Patent Office (EP)	BOR 00005/EPT	Pending	03769251.4		Via PCT
Japan (JP)	BOR 00005/JPT	Pending	2004-547447		Via PCT
USA (US)	BOR 00005/UST	Pending	10/533,290		Via PCT
WO		Expired	PCT/DK2003/000735		

(xii) Granzyme B cleavage of fusion proteins

Description of the invention:

Use of Granzyme B for cleavage of fusion proteins; Fusion proteins comprising a Granzyme B cleavage site; Human Granzyme B protease variant where Cys 228 is mutated to Phe.

Inventors:

Charlotte Harkjær Fynbo, Rikke Høegh Lorentzen

List of patents and patent applications claiming priority from:

Danish patent application No.: PA 2003 00616; Filing date: 23.04.2003.

USA, provisional patent application No.: 60/464,663; Filing date: 23.04.2003.

Joint ownership with F. Hoffmann-La Roche Ltd.

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia	BOR 00006/AUT	Pending	2004232405		Via PCT
Canada	BOR 00006/CAT	Pending	2,523,101		Via PCT
China	BOR 00006/CNT	Pending	200480014688.3		Via PCT
European Patent Office	BOR 00006/EPT	Pending	04729047.3		EP
India	BOR 00006/INT	Pending	2069/KOLNP/2005		Via PCT
Japan	BOR 00006/JPT	Pending	2006-504365		Via PCT

New Zealand	BOR 00006/NZT	Registered	543557		Via PCT
New Zealand		Pending	561162		Divisional
USA	BOR 00006/UST	Pending	10/553,869		Via PCT
WO		Expired	PCT/DK2004/000282		

(xiii) EPO-depot

Case dead

Description of the invention:

Pharmaceutical composition comprising a complex of non-covalently associated erythropoietin (EPO) and soluble erythropoietin binding protein (EPO-bp) and the use of such a composition in therapy, in particular for the treatment of diseases or conditions involving low red blood cell levels or deficient blood cell production.

Inventors:

Thor Las Holtet

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
DK	BOR 00007/DK/P1	Abandoned	PA 2003 01341		Priority

(xiv) HIV fusion inhibitor

Description of the invention:

Multimeric fusion proteins exhibiting anti-viral activity which comprises the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein fused to a multimerisation domain peptide.

Inventors:

Michael Etzerodt

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2004 00283; Filing date: 23-02-2004

US provisional patent application No.: 60/546,200; Filing date: 23.02.2004

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Brazil (BR)	BOR 00010/BRT	Pending	PI0507949-7		Via PCT
China (CN)	BOR	Pending	200580011458.6		Via PCT

	00010/CNT				
European Patent Office (EP)	BOR 00010/EPT	Pending	05706783.7		Via PCT
India (IN)	BOR 00010/INT	Pending			Via PCT
USA (US)	BOR 00010/US	Pending	11/064,115		Regular
WO		Expired	PCT/DK2005/000121		

(xv) TNF antagonists

Description of the invention:

Polypeptides and related compounds that can bind and act as antagonists of TNF.

Inventors:

Mikkel Holmen Andersen, Mette Munch, Helle Krogh Ottow, Thor Las Holtet, Josephus Dirk Nieland

Patents and patent applications claiming priority from:

Danish patent application No.: PA 2004 01813; Filing date: 22.11.2004

US provisional patent application No.: 60/629,343; Filing date: 22.11.2004

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
Australia (AU)	BOR 00011/AUT	Pending	2005306168		Via PCT
Brazil (BR)	BOR 00011/BRT	Pending	PI0518042-2		Via PCT
Canada (CA)	BOR 00011/CAT	Pending	2587948		Via PCT
China (CN)	BOR 00011/CNT	Pending	200580046429.3		Via PCT
European Patent Office (EP)	BOR 00011/EPT	Pending	05803991.8		Via PCT
India (IN)	BOR 00011/INT	Pending			Via PCT
Japan (JP)	BOR 00011/JPT	Pending	2007-541691		Via PCT
Korea, South (KR)	BOR 00011/KRT	Pending	2007-7013927		Via PCT
Norway (NO)	BOR 00011/NOT	Pending	20073239		Via PCT
New Zealand (NZ)	BOR 00011/NZT	Pending	555353		Via PCT

USA (US)	BOR 00011/UST	Pending	11/719,942		Via PCT
South Africa (ZA)	BOR 00011/ZAT	Pending	2007/05594		Via PCT
WO	BOR 00011/WO	Expired	PCT/DK2005/000742		PCT

(xvi) HSP70 domain

Description of the invention:

Domain in Heat Shock Protein 70 involved in the induction of autoimmune diseases such as Vitiligo

Inventors:

Josephus Dirk Nieland, Thor Las Holtet, Isabelle Caroline Le Poole

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
USA (US)	BOR 00012/UST	Pending	60/904,550		Provisional
USA (US)		Pending	60/960,022		Provisional

(xvii) Trimeric IL-Ra

Description of the invention:

Trimeric interleukin 1 receptor antagonist (IL-1Ra)

Inventors:

Josephus Dirk Nieland, Thor Las Holtet, Mikkel Holmen Andersen

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
USA (US)	BOR 00013/UST	Pending	60/978,254		Provisional

(xviii) MPB-DC-SIGN

Description of the invention:

Fusion proteins for treating cancer

Inventors:

Mikkel Holmen Andersen, Michael Etzerodt, Thor Las Holtet, Majbritt Hauge Kyneb

COUNTRY (CODE)	CASE REF	STATUS	APPLICATION NO.	PATENT NO.	TYPE
DENMARK (DK)		Pending	PA 2007 01589		Provisional
USA (US)		Pending	60,996,288		Provisional